Prothena (PRTA)
(Delayed Data from NSDQ)
$22.02 USD
+0.02 (0.09%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $22.07 +0.05 (0.23%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Prothena Corporation plc [PRTA]
Reports for Purchase
Showing records 201 - 220 ( 340 total )
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Phase I/II Data Presented at ASH Consistent with Full NEOD001 Data; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
ASH 2016: Additional Abstracts and Sessions of Interest
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
PRX002 with Higher CSF Levels Than Expected - Phase II up Next; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Reports 3Q16 Results with PRX002 Data Coming This Month; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Thinking about PRX002 as We Head Towards a First Look in Parkinson''s Patients; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Prothena Chooses Psoriatic Arthritis as Next Indication for PRX003; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Dale Schenk to Take Medical Leave ; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H